What are the diagnostic criteria for eosinophilic asthma?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 21, 2025 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

From the Guidelines

The diagnostic criteria for eosinophilic asthma include elevated blood eosinophil counts, elevated sputum eosinophil levels, and elevated fractional exhaled nitric oxide (FeNO) levels, with patients typically presenting with late-onset asthma and poor response to conventional inhaled corticosteroid therapy. According to the most recent study 1, asthma is characterized by respiratory symptoms that fluctuate over time in frequency and intensity and by variable airflow limitation, and is consistently reported as a major cause of chronic cough. The study also notes that non-invasive inflammatory markers such as blood or sputum eosinophil counts and fractional exhaled nitric oxide (F ENO) can provide additional evidence to support the need for corticosteroid treatment.

Some key features of eosinophilic asthma include:

  • Elevated blood eosinophil counts (typically ≥300 cells/μL)
  • Elevated sputum eosinophil levels (≥2-3% of total cells)
  • Elevated fractional exhaled nitric oxide (FeNO) levels (typically >50 parts per billion)
  • Late-onset asthma, often after age 12
  • Poor response to conventional inhaled corticosteroid therapy
  • Clinical features such as chronic rhinosinusitis, nasal polyps, and more severe asthma symptoms with frequent exacerbations despite adherence to standard treatments

The diagnosis of eosinophilic asthma often requires a combination of these findings, rather than a single test, with bronchoscopy with bronchoalveolar lavage sometimes performed to directly measure airway eosinophilia 1. This phenotype is important to identify as these patients often respond well to targeted biologic therapies such as anti-IL-5 medications (mepolizumab, reslizumab, benralizumab), anti-IL-4/IL-13 (dupilumab), or anti-IgE (omalizumab) treatments.

It's worth noting that an earlier study 2 found that F ENO can support a diagnosis of asthma, but its limitations arise from the heterogeneity of airway inflammation in asthma, and it may not always be associated with increased F ENO. However, the more recent study 1 provides a more comprehensive understanding of the diagnostic criteria for eosinophilic asthma.

From the Research

Diagnostic Criteria for Eosinophilia Asthma

The diagnostic criteria for eosinophilia asthma include:

  • Significantly elevated blood or sputum eosinophils and/or fractional exhaled nitric oxide 3
  • Peripheral blood eosinophilia, typically ≥500 cells/mm3, by pulmonary symptoms and physical examination findings that are nonspecific, and by radiographic evidence of pulmonary disease 4
  • Induced sputum cell count is the gold standard for identifying eosinophilic inflammation in asthma, although several noninvasive biomarkers, including fractional exhaled nitric oxide and periostin, are emerging as potential surrogates 5
  • Measurements of sputum eosinophils, blood eosinophils, FeNO, serum IgE, and periostin can be used as biomarkers to diagnose eosinophilic asthma 6

Biomarkers for Eosinophilic Asthma

Biomarkers that can be used to diagnose eosinophilic asthma include:

  • Blood eosinophils
  • Fractional exhaled nitric oxide (FeNO)
  • Serum IgE
  • Periostin
  • Sputum eosinophils These biomarkers can be used separately or in combination, and their accuracy to detect sputum eosinophilia depends on cut-off values 6

Importance of Accurate Diagnosis

Accurate diagnosis of eosinophilic asthma is essential to identify patients who may benefit from targeted therapies, such as monoclonal antibodies 3. Uncontrolled eosinophilic airway inflammation is associated with reduced response to glucocorticoids and increased risk of severe exacerbations 6.

Related Questions

In a 26-year-old woman with a history of intermittent asthma who works in a research laboratory with rats and has six months of worsening shortness of breath, nasal and conjunctival erythema, mild eosinophilia, expiratory wheezing, hyperinflated lungs on radiography, and airway wall thickening with regional air trapping on CT (computed tomography), what is the most likely diagnosis?
In a 40-year-old woman with severe asthma, peripheral eosinophilia, recent peripheral neuropathy, mild cardiomyopathy, and recurrent bilateral pulmonary infiltrates, what is the appropriate next step in management?
What is the recommended treatment approach for an adult with persistent asthma and an elevated blood eosinophil count who remains uncontrolled on inhaled corticosteroids?
Can elevated IgG (Immunoglobulin G) exposure to mold contribute to elevated eosinophil counts in patients with a history of respiratory issues and potential immunocompromised status?
What is the diagnostic approach for tropical pulmonary eosinophilia?
What is the maximum oral potassium dose a patient can take in one hour?
How to reduce pulmonary hypertension with Telmisartan (angiotensin II receptor antagonist) and Hydrochlorothiazide (HCTZ) (thiazide diuretic)?
What are the indications to start inotropes (inotropic agents) on a patient?
What causes ulcers on the fingertips, also known as digital (finger) ulcers?
What are the guidelines for completing an antibiotic course after missing doses?
How often should a pulse check be performed during Advanced Cardiovascular Life Support (ACLS)?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.